A Phase II Study of Campath-1H in Children With Acute Lymphoblastic Leukemia in Second or Greater Relapse or Twice Induction Failure
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Response rate to Campath-1H alone
研究概览
简要总结
This phase II trial is studying how well giving alemtuzumab with or without methotrexate and mercaptopurine works in treating young patients with relapsed acute lymphoblastic leukemia. Monoclonal antibodies such as alemtuzumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as methotrexate and mercaptopurine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more cancer cells.
详细描述
PRIMARY OBJECTIVES:
I. Determine the response rate to alemtuzumab alone and in combination with methotrexate and mercaptopurine in children with acute lymphoblastic leukemia in second or greater relapse or twice induction failure.
II. Determine the toxicity of these regimens in these patients.
SECONDARY OBJECTIVES:
I. Determine the pharmacokinetics of alemtuzumab in these patients. II. Determine the immune response in patients treated with alemtuzumab. III. Determine changes in the number of CD52-positive cells in the blood and marrow of patients treated with alemtuzumab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 30 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of acute lymphoblastic leukemia (ALL)
- •Meets 1 of the following criteria:
- •Second or subsequent bone marrow relapse
- •Failed ≥ 2 regimens for remission induction
- •Patients who relapse while receiving standard ALL maintenance chemotherapy do not require a waiting period prior to study entry
- •More than 25% blasts in bone marrow aspirate (M3 marrow)
- •CD52 expression on ≥ 25% of malignant cells at relapse
- •Philadelphia chromosome-positive patients must have failed prior imatinib mesylate
- •Performance status - Karnofsky 50-100% (for patients > 10 years of age)
- •Performance status - Lansky 50-100% (for patients ≤ 10 years of age)
- •At least 8 weeks
- •ALT ≤ 5 times upper limit of normal (ULN)
- •Bilirubin ≤ 1.5 times ULN
- •Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min
- •Creatinine normal for age
- •Pulse oximetry > 94%
- •No evidence of dyspnea at rest
- •No exercise intolerance
- •No serious uncontrolled infection
- •No autoimmune hemolytic anemia
- •No autoimmune thrombocytopenia
- •Not pregnant or nursing
- •No nursing for 3 months after study participation
- •Negative pregnancy test
- •Fertile patients must use effective contraception during and for 6 months after study participation
- •Seizure disorder allowed provided patients are on anticonvulsants and symptoms are well controlled
- •CNS toxicity ≤ grade 2
- •No other serious uncontrolled medical condition (e.g., diabetes)
- •Recovered from prior immunotherapy
- •At least 8 weeks since prior biologic agents (e.g., monoclonal antibodies)
- •More than 1 week since prior growth factor(s)
- •At least 4 months since prior stem cell transplantation
- •No evidence of active acute or chronic graft-versus-host disease post allogeneic stem cell transplantation
- •No prior alemtuzumab or its components
- •No other concurrent anticancer immunomodulating agents
- •Recovered from prior chemotherapy
- •One dose of prior intrathecal (IT) methotrexate, cytarabine, and hydrocortisone; IT cytarabine alone; or IT methotrexate alone allowed as part of initial diagnostic spinal tap
- •Prior hydroxyurea therapy allowed
- •No other concurrent anticancer chemotherapy agents
- •Prior steroid therapy allowed
- •More than 2 weeks since prior radiotherapy and recovered
排除标准
- 未提供
研究组 & 干预措施
Arm I
Course 1: Patients receive alemtuzumab IV over 2 hours on days 1-5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission (CR), partial remission (PR), or cytolytic PR at day 29, or patients with CNS disease that achieve a CNS 1 or CNS 2 status, proceed to course 2.
Courses 2 and 3: Patients receive alemtuzumab IV over 2 hours on days 1, 8, 15, and 22; methotrexate IV continuously over 24 hours on day 1 and then orally once daily on days 8, 15, and 22; and oral mercaptopurine once daily on days 1-28. Patients with a CR or PR at day 29 proceed to course 3. In course 3, patients receive alemtuzumab, methotrexate, and mercaptopurine as in course 2.
CNS prophylaxis*: Patients receive methotrexate intrathecally on day 1 of courses 2 and 3 on day 1 of courses 2 and 3.
NOTE: * CNS-negative patients receive methotrexate intrathecally on day 15 of course 1 and day 1 of courses 2 and 3.
干预措施: alemtuzumab (Biological)
Arm I
Course 1: Patients receive alemtuzumab IV over 2 hours on days 1-5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission (CR), partial remission (PR), or cytolytic PR at day 29, or patients with CNS disease that achieve a CNS 1 or CNS 2 status, proceed to course 2.
Courses 2 and 3: Patients receive alemtuzumab IV over 2 hours on days 1, 8, 15, and 22; methotrexate IV continuously over 24 hours on day 1 and then orally once daily on days 8, 15, and 22; and oral mercaptopurine once daily on days 1-28. Patients with a CR or PR at day 29 proceed to course 3. In course 3, patients receive alemtuzumab, methotrexate, and mercaptopurine as in course 2.
CNS prophylaxis*: Patients receive methotrexate intrathecally on day 1 of courses 2 and 3 on day 1 of courses 2 and 3.
NOTE: * CNS-negative patients receive methotrexate intrathecally on day 15 of course 1 and day 1 of courses 2 and 3.
干预措施: methotrexate (Drug)
Arm I
Course 1: Patients receive alemtuzumab IV over 2 hours on days 1-5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission (CR), partial remission (PR), or cytolytic PR at day 29, or patients with CNS disease that achieve a CNS 1 or CNS 2 status, proceed to course 2.
Courses 2 and 3: Patients receive alemtuzumab IV over 2 hours on days 1, 8, 15, and 22; methotrexate IV continuously over 24 hours on day 1 and then orally once daily on days 8, 15, and 22; and oral mercaptopurine once daily on days 1-28. Patients with a CR or PR at day 29 proceed to course 3. In course 3, patients receive alemtuzumab, methotrexate, and mercaptopurine as in course 2.
CNS prophylaxis*: Patients receive methotrexate intrathecally on day 1 of courses 2 and 3 on day 1 of courses 2 and 3.
NOTE: * CNS-negative patients receive methotrexate intrathecally on day 15 of course 1 and day 1 of courses 2 and 3.
干预措施: mercaptopurine (Drug)
结局指标
主要结局
Response rate to Campath-1H alone
时间窗: Day 29, course 1
Response to combined treatment with Campath-1H and chemotherapy
时间窗: Day 29, course 2
Tolerability of the combination therapy evaluated by dose-limiting toxicity
时间窗: Up to 8 years
次要结局
未报告次要终点